Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosing

Key secondary endpoint also met, showing a single evening dose of 250 mg GlyphAllo did not impair next-morning driving performance compared to placebo on Day 2

GlyphAllo was well-tolerated, with no serious adverse events reported

Company plans to submit results to the U.S. Food and Drug Administration as part of the ongoing development program for GlyphAllo

Seaport Therapeutics, Inc., (NASDAQ:SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo™ (SPT-300 or Glyph Allopregnanolone), a novel, Glyphed oral prodrug of allopregnanolone, in healthy volunteers. The trial evaluated the 375 mg dose of GlyphAllo, the highest dose currently being investigated in the Phase 2b BUOY-1 trial, as well as a 250 mg dose. The trial met its primary endpoint demonstrating that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosing. The key secondary endpoint was also met, showing that a single 250 mg dose of GlyphAllo did not impair next-morning driving performance compared to placebo on Day 2.